Federal Court Shuts Down Viatris Sitagliptin Challenge Following West Virginia Defeat
Originator Merck Has Settled With Nearly Half A Dozen Firms On Generic Production
Viatris has suffered a second defeat in its challenge to Merck’s sitagliptin dihydrogen phosphate exclusivity in the US Court of Appeals for the Federal Circuit, shortly after experiencing a similar blow in the District Court for the Northern District of West Virginia.
